Is MGTX or TTRX more profitable?

Turn Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Company Net Margins Return on Equity Return on Assets MeiraGTx -151.12% N/A -54.96% Turn Therapeutics N/A N/A N/A

Does the media prefer MGTX or TTRX?

In the previous week, MeiraGTx had 4 more articles in the media than Turn Therapeutics. MarketBeat recorded 6 mentions for MeiraGTx and 2 mentions for Turn Therapeutics. MeiraGTx's average media sentiment score of 0.68 beat Turn Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TTRX or COLL?

In the previous week, Collegium Pharmaceutical had 8 more articles in the media than Turn Therapeutics. MarketBeat recorded 10 mentions for Collegium Pharmaceutical and 2 mentions for Turn Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.46 beat Turn Therapeutics' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, TTRX or ORIC?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A

Is TTRX or ORIC more profitable?

Turn Therapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Oric Pharmaceuticals N/A -35.33% -33.31%

Does the media prefer TTRX or ORIC?

In the previous week, Turn Therapeutics and Turn Therapeutics both had 2 articles in the media. Oric Pharmaceuticals' average media sentiment score of 1.61 beat Turn Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to SDGR or TTRX?

In the previous week, Schrodinger had 5 more articles in the media than Turn Therapeutics. MarketBeat recorded 7 mentions for Schrodinger and 2 mentions for Turn Therapeutics. Schrodinger's average media sentiment score of 0.75 beat Turn Therapeutics' score of 0.00 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor WVE or TTRX?

In the previous week, WAVE Life Sciences had 15 more articles in the media than Turn Therapeutics. MarketBeat recorded 17 mentions for WAVE Life Sciences and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.00 beat WAVE Life Sciences' score of -0.19 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Turn Therapeutics (TTRX) Competitors

$8.36 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$8.36 0.00 (0.00%)

As of 07/31/2026 07:34 PM Eastern

Compare

TTRX vs. MGTX, COLL, ORIC, SDGR, and WVE

Should you buy Turn Therapeutics stock or one of its competitors? MarketBeat compares Turn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Turn Therapeutics include MeiraGTx (MGTX), Collegium Pharmaceutical (COLL), Oric Pharmaceuticals (ORIC), Schrodinger (SDGR), and WAVE Life Sciences (WVE).

How does Turn Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

67.5% of MeiraGTx shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Turn Therapeutics has lower revenue, but higher earnings than MeiraGTx. Turn Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$79.76M	13.69	-$114.20M	-$1.48	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

MeiraGTx currently has a consensus target price of $26.00, suggesting a potential upside of 120.53%. Turn Therapeutics has a consensus target price of $8.00, suggesting a potential downside of 4.31%. Given MeiraGTx's stronger consensus rating and higher possible upside, research analysts plainly believe MeiraGTx is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Turn Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Turn Therapeutics	N/A	N/A	N/A

In the previous week, MeiraGTx had 4 more articles in the media than Turn Therapeutics. MarketBeat recorded 6 mentions for MeiraGTx and 2 mentions for Turn Therapeutics. MeiraGTx's average media sentiment score of 0.68 beat Turn Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MeiraGTx beats Turn Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Collegium Pharmaceutical?

Turn Therapeutics (NASDAQ:TTRX) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Turn Therapeutics currently has a consensus price target of $8.00, indicating a potential downside of 4.31%. Collegium Pharmaceutical has a consensus price target of $57.50, indicating a potential upside of 62.48%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

Collegium Pharmaceutical has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Collegium Pharmaceutical	$796.33M	1.44	$62.87M	$2.04	17.35

Collegium Pharmaceutical has a net margin of 9.41% compared to Turn Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Collegium Pharmaceutical	9.41%	95.18%	16.39%

In the previous week, Collegium Pharmaceutical had 8 more articles in the media than Turn Therapeutics. MarketBeat recorded 10 mentions for Collegium Pharmaceutical and 2 mentions for Turn Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.46 beat Turn Therapeutics' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Collegium Pharmaceutical beats Turn Therapeutics on 12 of the 12 factors compared between the two stocks.

How does Turn Therapeutics compare to Oric Pharmaceuticals?

Turn Therapeutics (NASDAQ:TTRX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Turn Therapeutics presently has a consensus price target of $8.00, indicating a potential downside of 4.31%. Oric Pharmaceuticals has a consensus price target of $19.27, indicating a potential upside of 74.10%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Turn Therapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

In the previous week, Turn Therapeutics and Turn Therapeutics both had 2 articles in the media. Oric Pharmaceuticals' average media sentiment score of 1.61 beat Turn Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Turn Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Oric Pharmaceuticals beats Turn Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Turn Therapeutics compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Schrodinger had 5 more articles in the media than Turn Therapeutics. MarketBeat recorded 7 mentions for Schrodinger and 2 mentions for Turn Therapeutics. Schrodinger's average media sentiment score of 0.75 beat Turn Therapeutics' score of 0.00 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Turn Therapeutics' return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Turn Therapeutics	N/A	N/A	N/A

Schrodinger currently has a consensus target price of $20.25, suggesting a potential upside of 33.75%. Turn Therapeutics has a consensus target price of $8.00, suggesting a potential downside of 4.31%. Given Schrodinger's higher possible upside, analysts clearly believe Schrodinger is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

79.1% of Schrodinger shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Turn Therapeutics has lower revenue, but higher earnings than Schrodinger. Turn Therapeutics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$254.91M	4.38	-$103.26M	-$1.41	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Summary

Schrodinger beats Turn Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

89.7% of WAVE Life Sciences shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, WAVE Life Sciences had 15 more articles in the media than Turn Therapeutics. MarketBeat recorded 17 mentions for WAVE Life Sciences and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.00 beat WAVE Life Sciences' score of -0.19 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. Turn Therapeutics' return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Turn Therapeutics	N/A	N/A	N/A

Turn Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. Turn Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	25.41	-$204.38M	-$1.09	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

WAVE Life Sciences presently has a consensus price target of $23.88, suggesting a potential upside of 333.44%. Turn Therapeutics has a consensus price target of $8.00, suggesting a potential downside of 4.31%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe WAVE Life Sciences is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

WAVE Life Sciences beats Turn Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TTRX vs. The Competition

Export

Metric	Turn Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$249.04M	$11.71B	$6.86B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-44.00	799.05	282.30	24.66
Price / Sales	N/A	751.29	564.98	76.51
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	52.25	10.36	10.92	6.07
Net Income	-$3.19M	$2.82B	$3.49B	$347.99M
7 Day Performance	7.46%	-0.13%	-0.64%	-0.44%
1 Month Performance	17.42%	-3.99%	-5.24%	-4.81%
1 Year Performance	N/A	156.16%	61.98%	18.61%

Turn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TTRX Turn Therapeutics	0.7344 of 5 stars	$8.36 flat	$8.00 -4.3%	N/A	$249.04M	N/A	N/A	2
MGTX MeiraGTx	3.6136 of 5 stars	$12.10 -0.5%	$26.00 +114.9%	+54.1%	$1.13B	$81.39M	N/A	300	Gap Up
COLL Collegium Pharmaceutical	2.6513 of 5 stars	$35.59 +2.5%	$57.50 +61.6%	+17.7%	$1.13B	$780.57M	17.45	210	Upcoming Earnings
ORIC Oric Pharmaceuticals	2.5024 of 5 stars	$10.89 +1.3%	$19.27 +77.0%	+9.4%	$1.11B	N/A	N/A	80
SDGR Schrodinger	2.3877 of 5 stars	$15.13 +0.7%	$20.25 +33.8%	-22.5%	$1.11B	$255.87M	N/A	790	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TTRX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Turn Therapeutics (TTRX) Competitors

TTRX vs. MGTX, COLL, ORIC, SDGR, and WVE

How does Turn Therapeutics compare to MeiraGTx?

Summary

How does Turn Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Turn Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Turn Therapeutics compare to Schrodinger?

Summary

How does Turn Therapeutics compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Turn Therapeutics (TTRX) Competitors

TTRX vs. MGTX, COLL, ORIC, SDGR, and WVE

How does Turn Therapeutics compare to MeiraGTx?

Do institutionals and insiders hold more shares of MGTX or TTRX?

Which has better valuation & earnings, MGTX or TTRX?

Do analysts recommend MGTX or TTRX?

Is MGTX or TTRX more profitable?

Does the media prefer MGTX or TTRX?

Summary

How does Turn Therapeutics compare to Collegium Pharmaceutical?

Do analysts rate TTRX or COLL?

Which has better earnings & valuation, TTRX or COLL?

Is TTRX or COLL more profitable?

Does the media prefer TTRX or COLL?

Summary

How does Turn Therapeutics compare to Oric Pharmaceuticals?

Do analysts rate TTRX or ORIC?

Is TTRX or ORIC more profitable?

Does the media prefer TTRX or ORIC?

Which has preferable earnings and valuation, TTRX or ORIC?

Do insiders & institutionals have more ownership in TTRX or ORIC?

Summary

How does Turn Therapeutics compare to Schrodinger?

Does the media refer more to SDGR or TTRX?

Is SDGR or TTRX more profitable?

Do analysts recommend SDGR or TTRX?

Do insiders & institutionals hold more shares of SDGR or TTRX?

Which has better earnings and valuation, SDGR or TTRX?

Summary

How does Turn Therapeutics compare to WAVE Life Sciences?

Do insiders & institutionals hold more shares of WVE or TTRX?

Does the media favor WVE or TTRX?

Is WVE or TTRX more profitable?

Which has preferable earnings and valuation, WVE or TTRX?

Do analysts rate WVE or TTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools